Diamyd Medical Seeks Faster FDA Approval
Diamyd Medical is making notable progress in its quest for an accelerated approval pathway in the United States for its innovative antigen-specific immunotherapy, Diamyd (rhGAD65/alum). This groundbreaking treatment is designed to help preserve the body's ability to produce insulin in individuals diagnosed with Stage 3 Type 1 Diabetes.
Insights from the Study and Next Steps
The company is leveraging findings from an interim readout of its ongoing Phase 3 trial, known as DIAGNODE-3, as a vital part of its Biologics License Application (BLA). The interim data is expected to shed light on key aspects of Diamyd's effectiveness and may facilitate quicker access to this promising therapy for patients.
Timeline for Interim Study Results
Results from this important analysis are anticipated to be available around March 2026. Ulf Hannelius, the CEO of Diamyd Medical, underscores the urgency of this initiative. He states, "We are dedicated to collaborating closely with our partners and the FDA to expedite the availability of Diamyd for patients, as the interim findings from DIAGNODE-3 represent a crucial milestone for us. Our optimism is further supported by the favorable outcomes from a recent futility analysis."
Understanding Accelerated Approval Pathways
The U.S. FDA has indicated that Diamyd may qualify for accelerated approval based on evidence demonstrating significant treatment-related improvements in C-peptide levels, which are a key indicator of the body's insulin production, following treatment with Diamyd. This accelerated approval process allows essential medications for serious conditions to reach the market more quickly when they show substantial benefits through surrogate endpoints.
Preparing for BLA Submission
In preparation for the BLA under the FDA's Accelerated Approval Program, Diamyd Medical is currently conducting thorough assessments, analyzing data from approximately 170 participants who have completed their 15-month evaluations. This includes safety data from additional participants in the DIAGNODE-3 trial, further strengthening their evidence base.
Overview of the DIAGNODE-3 Trial
The DIAGNODE-3 trial is set to enroll around 330 patients by the end of 2025 and is being conducted across eight European countries as well as the U.S. The trial focuses primarily on patients who have recently been diagnosed with Stage 3 Type 1 Diabetes. Notably, it targets individuals with the HLA DR3-DQ2 genotype, a specific subgroup that has shown a positive response to Diamyd in previous studies.
About Diamyd Medical
Diamyd Medical is committed to developing targeted therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd (rhGAD65/alum) is recognized for its potential to preserve endogenous insulin production and has received both Orphan Drug Designation and Fast Track Designation from the FDA for treating various stages of Type 1 Diabetes. The company is currently conducting the confirmatory Phase III trial, DIAGNODE-3, and is actively recruiting participants in multiple countries, including the U.S.
Recent Developments and Future Prospects
Recent findings from large-scale meta-analyses and the company’s Phase IIb trial have revealed promising outcomes for Diamyd. The method of injecting directly into a lymph node enhances treatment delivery and optimizes patient responses. Additionally, Diamyd Medical is in the process of establishing a biomanufacturing facility in Umeå, Sweden, aimed at producing recombinant GAD65 protein, which is the active component of Diamyd.
Contact Information
For more information, please reach out to Ulf Hannelius, the President and CEO, at +46 736 35 42 41. Diamyd Medical’s B-share is traded on the Nasdaq First North Growth Market under the ticker DMYD B, with FNCA Sweden AB serving as the Certified Adviser.
Frequently Asked Questions
What is Diamyd Medical pursuing with its therapies?
Diamyd Medical is focused on an accelerated approval pathway for its immunotherapy treatment for Type 1 Diabetes.
What study is central to Diamyd's approval process?
The DIAGNODE-3 trial serves as a fundamental study from which interim results will be used for regulatory approval.
How does accelerated approval work?
Accelerated approval allows drugs to be approved based on early evidence that suggests they are likely to provide a clinical benefit.
What is the main objective of the DIAGNODE-3 trial?
The trial aims to evaluate the efficacy and safety of Diamyd in recently diagnosed patients with Type 1 Diabetes.
How can I reach Diamyd Medical for inquiries?
You can contact Ulf Hannelius, the CEO, at +46 736 35 42 41 for further information.
